ZIOP-PGEN Fundamental & Technical Discussion Board - Interesting - ZIOP-PGEN Fundamental & Technical Discussion Board - InvestorVillage

ZIOP-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ZIOP-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message


Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  24978 of 25151  at  9/24/2021 3:00:01 PM  by


The following message was updated on 9/24/2021 4:02:30 PM.


Posted recently by Frank on another board...


There is logic for a rise in ZIOP share price. In January of 2017, a Cooperative Research and Development Agreement (acronym CRADA) was signed between the National Cancer Institute and Ziopharm to explore the use of Ziopharms Sleeping Beauty transposen in the targeting of neoantigens to treat solid cancers. In June of 2019, the NCI announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy utilizing Ziopharms Sleeping Beauty platform.

However, while the Phase 2 trial was to begin in 2019, the NCI shut down its cell therapy lab and erected a new facility, incorporating modern and state-of-the-art automation, and it is expected to be commissioned in this fall ( 2021).

In general description, the objective of a CRADA is to place new and promising technology, developed by the NCI, into the hands of enterprise and engage the genius of industry to improve their solutions and place them into the public domain as an innovative benefit. As an oncology reference, the NCI CRADA with Kite Pharmaceutical in 2012 led to the worlds first regulatory approval of a CAR-T therapy against blood cancers. In thethis new CRADA the NCI, led by Dr. Steven Rosenberg, who has six decades of research, has made public statements that that TCR-T therapy is their finally found blueprint for success against solid cancers. Approximately 1.2 million Americans will be diagnosed with solid cancers every year and roughly six hundred thousand will die each year from solid cancers where best care did not succeed.

During the balance of this year and the first half of next year, the TCR-T trial will commence at the NCIs new lab in Gaithersburg MD as a phase two at Ziopharms facility at a Houston leased space at MD Anderson, and at support cell engineering firm, KBI Biopharma in Houston. Proof of concept is complete. Within one year, likely before June, 2022, initial ORR data will be published to show initial results across an array of solid tumor site of the body.

Kite was acquired by Gilead for $11 billion where the CAR-T target was blood cancers. For this CRADA addressing the remaining 90% that are solid cancers, there is logically a massive potential in risk/reward the risk is substantially reduced by Dr. Rosenbergs initial four years of research in TCR-T with Sleeping Beauty (over 100 patients) which elevate the solution as a phase two prospect.

The crux: Our bodys naturally present the cancer signature as a neoantigen on the surface of solid tumor cells. The NCI has developed a process to find and define those neoantigens, employing Sleeping Beauty to facilitate the interrogation, and Sleeping Beauty then delivers the cancer solution -- lock-on arms to the cancer cell (the Tcell receptors) and also deliver the killing blow with invigorated, targeted killer Tcells of the immune system. Sleeping Beauty (SB) attributes support efficacy, safety, precision, multiple cancer targets in one infusion (since virtually all solid cancers have at least one patient-specific and many times, multiple distinct neoantigens (typically two or more, up to six). SB also provides a rapid speed of expansion in the body and a low cost of process. The SB transposen is drawn from the patients own body to perform as a homologous vector for treatment, enabling personalized cancer therapy to treat the patients unique cancer signature.

     e-mail to a friend      printer-friendly     add to library      
Recs: 35  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
24979 Re: Interesting latebloomer 9 9/24/2021 3:47:09 PM

Financial Market Data provided by